06.06.2018
- BioMarin’s Palynziq has been approved by the US Food and Drug Administration (FDA) to reduce blood phenylalanine (Phe) concentrations in adults with phenylketonuria (PKU), a rare...
18.06.2013
- ViroPharma is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter. While...
09.01.2013
- BioMarin Pharmaceutical, which makes high-priced drugs used to treat rare diseases, would not consider a buy-out offer for even a 25-30% premium, according to the company's chief...
03.01.2013
- Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year. The following...
03.01.2013
- The Western world's first drug to fix faulty genes promises to transform the lives of patients with an ultra-rare disease that clogs their blood with fat. The only snag is the...
18.07.2012
- Large investors in U.S. biotech companies are likely to capture serious windfall profits as deal activity picks up in the sector. A Reuters analysis of investors' average cost...
31.01.2011
- Major drug makers are looking for products by purchasing smaller companies, creating many value opportunities, Barron's reported in its Jan. 31 edition. Among the companies that...
